These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 10632085)
1. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. Behnia K; Boroujerdi M J Pharm Pharmacol; 1999 Nov; 51(11):1275-82. PubMed ID: 10632085 [TBL] [Abstract][Full Text] [Related]
2. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats. Vaidyanathan S; Boroujerdi M Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735 [TBL] [Abstract][Full Text] [Related]
3. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Licata S; Saponiero A; Mordente A; Minotti G Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659 [TBL] [Abstract][Full Text] [Related]
4. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats. Ramanathan-Girish S; Boroujerdi M J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551 [TBL] [Abstract][Full Text] [Related]
5. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Booth CL; Brouwer KR; Brouwer KL Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873 [TBL] [Abstract][Full Text] [Related]
6. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity. El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278 [TBL] [Abstract][Full Text] [Related]
7. Investigation of the enterohepatic recirculation of Adriamycin and its metabolites by a linked-rat model. Behnia K; Boroujerdi M Cancer Chemother Pharmacol; 1998; 41(5):370-6. PubMed ID: 9523732 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. Yoon EJ; Shim HJ; Lee JJ; Lee SD; Kim WB; Yang J; Lee MG Drug Metab Dispos; 1997 Jan; 25(1):66-74. PubMed ID: 9010632 [TBL] [Abstract][Full Text] [Related]
9. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism. Zhou F; Hao G; Zhang J; Zheng Y; Wu X; Hao K; Niu F; Luo D; Sun Y; Wu L; Ye W; Wang G Br J Pharmacol; 2015 Dec; 172(23):5690-703. PubMed ID: 25363561 [TBL] [Abstract][Full Text] [Related]
10. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Forrest GL; Gonzalez B; Tseng W; Li X; Mann J Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643 [TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro. Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072 [TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Minotti G; Saponiero A; Licata S; Menna P; Calafiore AM; Teodori G; Gianni L Clin Cancer Res; 2001 Jun; 7(6):1511-5. PubMed ID: 11410484 [TBL] [Abstract][Full Text] [Related]
13. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin. Darvari R; Boroujerdi M Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726 [TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Jacquet P; Averbach A; Stuart OA; Chang D; Sugarbaker PH Cancer Chemother Pharmacol; 1998; 41(2):147-54. PubMed ID: 9443628 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of carbonyl reduction in subcellular fractions and different organs in rodents. Oppermann UC; Maser E; Mangoura SA; Netter KJ Biochem Pharmacol; 1991 Dec; 42 Suppl():S189-95. PubMed ID: 1768277 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib. Zhou ZY; Wan LL; Yang QJ; Han YL; Li Y; Yu Q; Guo C; Li X Toxicol Appl Pharmacol; 2013 Oct; 272(1):238-44. PubMed ID: 23770382 [TBL] [Abstract][Full Text] [Related]
17. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. Bains OS; Grigliatti TA; Reid RE; Riggs KW J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989 [TBL] [Abstract][Full Text] [Related]
18. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142 [TBL] [Abstract][Full Text] [Related]
19. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita). Gilbert CM; Filippich LJ; McGeary RP; Charles BG Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005 [TBL] [Abstract][Full Text] [Related]
20. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]